AMPE vs. AVTX, SLRX, BLCM, PTPI, ADIL, ATNF, INM, PHIO, UPC, and NBSE
Should you be buying Ampio Pharmaceuticals stock or one of its competitors? The main competitors of Ampio Pharmaceuticals include Avalo Therapeutics (AVTX), Salarius Pharmaceuticals (SLRX), Bellicum Pharmaceuticals (BLCM), Petros Pharmaceuticals (PTPI), Adial Pharmaceuticals (ADIL), 180 Life Sciences (ATNF), InMed Pharmaceuticals (INM), Phio Pharmaceuticals (PHIO), Universe Pharmaceuticals (UPC), and NeuBase Therapeutics (NBSE). These companies are all part of the "pharmaceutical preparations" industry.
Ampio Pharmaceuticals (NYSE:AMPE) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations.
Ampio Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
Avalo Therapeutics has a consensus price target of $10.00, indicating a potential upside of 7,042.86%. Given Avalo Therapeutics' higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than Ampio Pharmaceuticals.
Ampio Pharmaceuticals has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -146.01%. Avalo Therapeutics' return on equity of 0.00% beat Ampio Pharmaceuticals' return on equity.
In the previous week, Ampio Pharmaceuticals and Ampio Pharmaceuticals both had 2 articles in the media. Ampio Pharmaceuticals' average media sentiment score of 0.79 beat Avalo Therapeutics' score of 0.40 indicating that Ampio Pharmaceuticals is being referred to more favorably in the media.
3.1% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.3% of Avalo Therapeutics shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 45.4% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Avalo Therapeutics received 4 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 26.67% of users gave Avalo Therapeutics an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.
Ampio Pharmaceuticals has higher earnings, but lower revenue than Avalo Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Avalo Therapeutics beats Ampio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Ampio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMPE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ampio Pharmaceuticals Competitors List
Related Companies and Tools